<DOC>
	<DOC>NCT02474680</DOC>
	<brief_summary>This is a non-randomized, single-case design of pharmacogenetic implementation in a mental health patient population of subjects taking antipsychotics and/or antidepressants.</brief_summary>
	<brief_title>Evaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes</brief_title>
	<detailed_description>This is a non-randomized, single-case design of pharmacogenetic implementation in a mental health patient population of subjects taking antipsychotics and/or antidepressants. Retrospective and prospective data will be collected on all subjects before and after pharmacogenetic recommendations have been made. Retrospective data will be collected for the previous 12 months before pharmacogenetic recommendations are made and prospective data will be collected for 12 months after pharmacogenomic recommendations have been made.</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<criteria>Must be taking either an antidepressant or an antipsychotic medication Must provide informed consent Must have Avera Health Plans insurance coverage Must have three months of participation in the Avera Care Coordination Program Must not be pregnant or breastfeeding Must not have an active and/or unstable diagnosis of substance abuse Must not have a primary diagnosis of dementia, bulimia, or anorexia nervosa disorder Must not have had a previous pharmacogenetic evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>depression</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>MDD</keyword>
	<keyword>mental health</keyword>
	<keyword>pharmacogenomics</keyword>
	<keyword>personalized medicine</keyword>
	<keyword>precision medicine</keyword>
	<keyword>anti-depressants</keyword>
</DOC>